Stock Update: AbbVie Inc (NYSE:ABBV) – AbbVie to Present Late-breaker PEARL-III Study in Patients with Chronic Hepatitis C at the 21st Conference on Retroviruses and Opportunistic Infections

March 03, 2014 at 15:31 PM EST

[PR Newswire] – BOSTON, March 3, 2014 /PRNewswire/ — The first detailed results from AbbVie’s (ABBV) pivotal phase III study, PEARL-III, were presented today as part of the 21st Conference on Retroviruses and . . . → Read More: Stock Update: AbbVie Inc (NYSE:ABBV) – AbbVie to Present Late-breaker PEARL-III Study in Patients with Chronic Hepatitis C at the 21st Conference on Retroviruses and Opportunistic Infections Similar Articles: Company Update: Texas Instruments Inc (NASDAQ:TXN) – TI CEO Rich Templeton to speak at Morgan Stanley investor conference Merck & Co. Inc. (NYSE:MRK) – 8:31 am Merck initiates rolling submission of U.S. Biologics License Application for MK-3475, an investigational Anti-PD-1 Immunotherapy, in patients with advanced melanoma; expects to complete application in 1H14 AbbVie Inc. (NYSE:ABBV) ~ AbbVie’s hepatitis C treatment helps 96 pct of patients in trial

AbbVie Inc (NYSE:ABBV) [PR Newswire] – BOSTON, March 3, 2014 /PRNewswire/ — The first detailed results from AbbVie’s (ABBV) pivotal phase III study, PEARL-III, were presented today as part of the 21st Conference on Retroviruses and Opportunistic Infections (CROI) press conference and will also be presented as a late-breaker at the conference on March 4. PEARL-III evaluated the efficacy and safety of 12 weeks of treatment with AbbVie’s investigational therapy with or without ribavirin (RBV) in … [visit site to read more]